MUDIA Lab is focused on developing novel quantitative MRI techniques and analysis methods on CNS and musculoskeletal system. 

The Louros Lab uses a hybrid approach combining molecular biophysics, structural biology, and bioinformatics to investigate protein stability, misfolding, and aggregation, with a particular interest in neurodegenerative diseases.

The Ranjan Lab’s mission is to develop and translate novel immunotherapies, with a particular focus on addressing malignant cancers in humans and animals.

At the Fu Lab of human neuroscience we investigate the neural bases of cognitive control.

The Henning lab develops novel ultra-high field MRI and metabolic MRI methodology for human application and translates it to neuroscientific, physiological and clinical trials in brain, spine, heart and muscle disorders. 

BiMIR aims at pushing the state of the art in clinical diagnosis and benefit to patients by developing novel medical imaging technologies and enhancing our understanding of the underlying tissue health conditions.

The Dr. Zou's CPI lab is directed by Dr. Qing Zou and it works closely with a cross-disciplinary team (clinicians, scientists, fellows) to develop and translate novel MRI techniques for cardiopulmonary MRI for patients with congenital and acquired heart diseases. The research involves different aspects of MRI, including image acquisition and reconstruction, post-processing, quantitative image analysis, pre-clinical investigation, and clinical translation and evaluation. The lab has access to a cardiac-dedicated clinical 1.5T scanner (Philips), a research-dedicated low-field 0.55T MR scanner (Siemens), three research-dedicated 3T scanners (Philips, Siemens, GE). The lab also has access to a high-field 7T research scanner (Philips) for research on the high-field scanner. Some of the scanners also have the capability to do multi-nuclear imaging.

Harnessing the power of light to develop methods to understand, diagnose, & treat diseases. The unique strength of the Achilefu Lab (Optical Radiology Lab, ORL) is the ability to develop complete solutions from conception, implementation, and validation to human clinical care. We aim to change the way medicine is practiced.

Multidisciplinary research to beat cancer

SPIL is dedicated to advancing patient care through the development and validation of cutting-edge radionuclide imaging technologies for single photon emission computed tomography (SPECT) and positron emission tomography (PET). By harnessing the power of deep learning, we aim to address key limitations of PET and SPECT imaging—such as low spatial resolution and slow data acquisition—to significantly enhance diagnostic capabilities.